The efficacy of acupuncture for the treatment and the fertility improvement in child-bearing period female with Hashimoto Disease

A randomized controlled study

Fangyuan Li, PhD\textsuperscript{a}, Zhang Qi, PhD\textsuperscript{a}, Lu Hua, PhD\textsuperscript{a,b,*}, Xinxin Wang, PhD\textsuperscript{c}, Mi Ling, MD\textsuperscript{d}, Du Juan, PhD\textsuperscript{d}

Abstract

Background: Hashimoto thyroiditis (HT) is highly prevalent among reproductive-aged women and has a substantial negative impact on fertility. Currently, there is no specific treatment for Hashimoto thyroiditis. We hypothesize that acupuncture can halt or delay the progression of HT and improve fertility in child-bearing period female. We therefore designed a randomized controlled trial to test this hypothesis by comparing the therapeutic effect of acupuncture vs sham acupuncture in patients with Hashimoto thyroiditis.

Methods: In this randomized controlled study, a total of 284 eligible patients will be assigned to acupuncture group (n=142) or sham acupuncture group (n=142) in a 1:1 ratio. All patients will receive 36 sessions in total for 12 consecutive weeks with the same acupoint prescription (RN23, ST9, RN17, RN4, RN6, ST36, SP6, KI6). The primary assessment is the titers of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb). Secondary outcomes include the thyroid function, ovarian function, the rate of primary ovarian insufficiency, and pregnancy outcome. The thyroid function and thyroid antibodies tests will be measured at weeks 0, 4, 8, and 12 after randomization. The ovarian function will be examined on the 2nd to 4th day of the menstrual period in the 1st month, 2nd month and 3rd month compared with baseline. Both the pregnancy outcome and the rate of primary ovarian insufficiency will be evaluated 1 year after treatment.

Discussion: This will be the first large-scale trial specifically evaluating acupuncture therapy in child-bearing period female with Hashimoto thyroiditis. If the study confirms the effectiveness of acupuncture treatment, more consistent acupuncture therapy can be set up for clinical practice.

Trial registration: Chinese Clinical Trials Register identifier, ChiCTR2000031320, registered on 27 March 2020.

Abbreviations: AITD = autoimmune thyroid disease, AMH = anti-Müllerian hormone, CONSORT = Consolidated Standards of Reporting Trials, CRF = case record form, E2 = estradiol, EA = electroacupuncture, FSH = follicle-stimulating hormone, FSH = Follicle-Stimulating Hormone, FT4 = free thyroxine, HPG = hypothalamic-pituitary-gonadal, HPT = hypothalamic–pituitary–thyroid, HT = Hashimoto’s thyroiditis, ITT = intention-to-treat, LH = luteinizing hormone, LH = Luteinizing Hormone, LT4 = levothyroxine, M ± IQR = Medians ± Interquartile Range, M±SD = Mean ± Standard Deviation, OH = overt hypothyroidism, POI = premature ovarian failure, POI = premature ovarian insufficiency, RCT = randomized controlled trial, SCH = subclinical hypothyroidism, SPIRIT = Standard Protocol Items: Recommendations for Interventional Trials, STRICTA = Standards for Reporting Interventions in Clinical Trials of Acupuncture, T3 = triiodothyronine, T4 = tetraiodothyronine-4, TAI = thyroid autoimmunity, TCM = traditional Chinese medicine

FL and ZQ have contributed equally to this work.

The recruitment of patients will start on April 1, 2020, and it is expected that by October 1, 2020, the required sample size will be reached.

Ethical approval has been obtained from the Sichuan Regional Ethics Review Committee on Traditional Chinese Medicine (an ethics approval number of 2019KL-072)

This study is financially supported by the Ministry of Science and Technology of the People’s Republic of China.

This trial was financially supported by funds from the Ministry of Science and Technology of the People’s Republic of China (grant number 2018YFC1704305).

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

* Correspondence: Lu Hua, Chengdu University of Traditional Chinese Medicine Affiliated Hospital, NO.39 Shi-er-qiao Road, Chengdu 610075, Sichuan Province, PR China (e-mail: 18982088525@126.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Li F, Qi Z, Hua L, Wang X, Ling M, Juan D. The efficacy of acupuncture for the treatment and the fertility improvement in child-bearing period female with Hashimoto Disease: a randomized controlled study. Medicine 2020;99:27(e20909).

Received: 22 May 2020 / Accepted: 26 May 2020

http://dx.doi.org/10.1097/MD.00000000000020909
1. Introduction

Hashimoto thyroiditis (HT) known as autoimmune thyroiditis is a common autoimmune thyroid disease (AITD) and endocrine disorder. Surveys have shown that the prevalence of thyroid autoimmunity (TAI) and HT is 6% to 20% and 5% to 15% among reproductive-aged women, respectively. HT is characterized by increased levels of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb), diffuse lymphocytic infiltration of the thyroid gland, manifestations of goitrous or atrophic gland, and frequent thyroid dysfunction in varying degrees. HT is the most common cause of hypothyroidism. The pathogenesis is thought to be an immunologic attack that the presence of TPOAb tends to correlate with thyroid damage and lymphocytic inflammation. TPOAb is directly cytotoxic to thyrocytes. In patients who have circulating thyroid peroxidase antibodies, there is a greater risk of progression from subclinical to overt hypothyroidism. A previous study indicates that largely increased levels of TPOAb are associated with a moderately increased risk of developing hypothyroidism in the patients of Hashimoto thyroiditis remained euthyroid. An epidemiological survey with a 20-year follow-up showed that the lifetime risk of incident hypothyroidism was 4% among TPOAb negative women, 23% for women with low-level TPOAb, 33% for those with mid-level TPOAb, and 53% for those with high TPOAb. Most cases of Hashimoto thyroiditis are considered to be the early stage of hypothyroidism. According to studies, 4% to 8% of the reproductive-age population suffered from subclinical hypothyroidism (SCH) with elevated thyroid stimulating hormone (TSH) more than 4.5 to 5.0 mIU/L and normal free thyroxine (FT4) levels concentration. The risk of progression from SCH to overt hypothyroidism (OH) ranges between 2% and 5% a year. It is well known that thyroid hormones play important roles during the development and maintenance of reproductive function in women. Numerous studies have suggested that thyroid autoimmunity and hypothyroidism associated with an adverse effect on fertility as well as pregnancy.

For two decades, the association between TAI and reproductive failure has gained attention. Fertility is impaired in women with autoimmune thyroid disease. An extensive meta-analysis study reported that the presence of TPOAb combined with normal thyroid function was associated with an increased risk of unexplained subfertility, implantation failure, miscarriage, recurrent miscarriage, preterm birth, and maternal post-partum thyroiditis. A prospective study confirmed that the prevalence of TPOAb was greater (18%) in infertile women than that in healthy and fertile controls (8%). Autoimmune thyroid disorder and hypothyroidism have a negative impact on ovarian function. Women withAITD have lower serum anti-Müllerian hormone (AMH) levels compared with age-matched controls, which means women with AITD have prematurely aging ovaries. A prospective controlled trial revealed that 5% of patients of premature ovarian insufficiency (POI) presented highly elevated antithyroid antibodies. Besides, 24.1% of patients with premature ovarian failure (POF) had thyroid peroxidase autoantibodies. Idiopathic low ovarian reserve was associated with more frequent positive TPOAb in Chinese women. The human ovary is often the target of an autoimmune attack. In this context, HT is likely to be associated with ovarian dysfunction and diminished ovarian reserve. TPOAb has been detected in all samples of follicular fluid obtained from women with thyroid autoimmunity, while they were absent in women without thyroid autoimmunity. In these patients with HT, the levels of TPOAb in ovarian follicular fluid is positively correlated with serum antibody levels. Monteleone et al speculated that TPOAb might pass through the blood follicle barrier during follicular evolution and damage growing follicles and oocytes via thyroid hormone receptors on granulosa cells, which may result in decreasing the quality and development potential of oocyte. TPOAb targets TPO antigen on granulosa cells, creating a hostile local immune microenvironment around the oocyte. Subclinical or overt hypothyroidism is often caused by HT, which is associated with a diminished ovarian reserve in infertile patients of reproductive age. Recently, a retrospective study showed that SCH was associated with decreased ovarian reserve during later reproductive age. Therefore, Hashimoto thyroiditis has a substantial negative impact on the fecundity of reproductive-aged women. Impaired fertility has become a major public health problem that is associated with an increasing burden on society.

To date, there are no specific therapies to effectively reduce the autoantibody level of HT. Patients with HT who have normal thyroid function and no obvious symptoms of oppression should be followed up and monitored thyroid function regularly. Current therapeutic strategies for HT with normal thyroid function in the early stages include Se supplementation, glucocorticoids, and vitamin D. However, the available data on beneficial effects of Se on thyroid autoimmune parameters are limited. On the other hand, caution should be taken when long-term selenium supplementation, the increased risk of type 2 diabetes was observed in a randomized clinical trial. Only an ambiguous causal relationship and few intervention studies reported that Vitamin D is beneficial in the management of thyroid disease, so the therapeutic potential of vitamin D remains debated. Although some small trials appear promising of glucocorticoids, corticosteroid use has many negative effects on key aspects of early pregnancy. Once overt hypothyroidism is present, levothyroxine (LT4) is the treatment of choice for Hashimoto thyroiditis. Patients with HT who have the mere presence of detectable TPO antibodies does not, however, advocate empiric treatment with thyroid hormone. According to one study, women that are considered euthyroid, before pregnancy, are reclassified as having subclinical hypothyroidism, in cases of TSH between 2.5 and 4 mIU/L. Most endocrinologists use a TSH value of 2.5 mIU/L as the threshold for diagnosing hypothyroidism and starting levothyroxine in pregnant women because of an evident association between mild thyroid impairment and adverse outcomes in pregnancy. LT4 supplementation can slow the progression of
HT, control the early stage of hypothyroidism, and support follicular development.\cite{199} The American Thyroid Association’s recommendations for LT4 treatment also be considered for TPOAb positive women with normal thyroid function, although the quality of evidence is low.\cite{50} However, LT4 treatment before pregnancy in women is lacking sufficient data. An ideal TSH value before pregnancy can initiate a typical starting dose LT4 therapy (25–50 µg/d) When considering the potential benefits and risks minimization.\cite{50}

According to the World Health Organization (WHO), acupuncture can be used to treat thyroid diseases. As integrative therapy or alternative medicine, acupuncture is safe and economical. Acupuncture can reduce symptoms and improve relevant biomarkers of thyroid disease patients.\cite{51} MOK pharmacopuncture (a new form of acupuncture treatment) can regulate the imbalance of Th1/Th2 cytokines and help to suppress autoimmune response.\cite{52} Acupuncture can regulate the indexes related to immune function and correct the immune dysfunction to some extent, which is possibly the action mechanism of acupuncture-moxibustion in treating HT.\cite{53} Electroacupuncture (EA) intervention can regulate the thyroid hormone.\cite{54} The connection between thyroid and fertility is mainly based on cross-talk between the hypothalamic–pituitary–thyroid (HPT) axis and the hypothalamic–pituitary–gonadal (HPG) axis.\cite{16} The electroacupuncture has a benign regulating effect on the key hormones in the pituitary-target gland axis, such as thyroid-stimulating hormone (TSH), triiodothyronine (T3), tetraiodothyronine (T4), estradiol (E2), luteinizing hormone (LH) and follicle-stimulating hormone (FSH).\cite{16,55} Therefore, we can draw the preliminary conclusion that acupuncture can delay the progress of Hashimoto’s thyroiditis and improve its fertility. Although acupuncture is increasingly used as a nonpharmacologic therapy in clinical practice, the level of available evidence is rated as “low”. We designed an RCT to evaluate the effects of acupuncture on halting or delaying the progression of HT and fertility improving in child-bearing period female.

2. Methods and analysis

2.1. Design

A single-center, patient-blinded, randomized controlled trial (RCT) is currently being performed. Acupuncture will be compared with sham acupuncture to determine if acupuncture has an effect on the reduction of antibody (TPOAb or TGAb) and fertility improving. The trial will be conducted in the Department of gynecology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine. The protocol will be reported following the Consolidated Standards of Reporting Trials (CONSORT) statement and the Revised Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA).\cite{56,57} The flowchart of the trial is shown in Figure 1. The study schedule is detailed in Table 1. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided as Additional File 1.

2.2. Ethic approval

The research protocol is performed in accordance with the principles of the Declaration of Helsinki\cite{58} and has been approved by the Sichuan Regional Ethics Review Committee on Traditional Chinese Medicine (approval no. 2019KL-072). We registered the study on the Chinese Clinical Trial Registry (Registration No. ChiCTR2000031320).

2.3. Participants

A total of 284 women with HT in child-bearing period will be enrolled in this study after their informed consents are obtained. The diagnosis of HT based on circulating antibodies to thyroperoxidase (mainly thyroperoxidase and thyroglobulin) and reduced echogenicity on thyroid sonogram.\cite{17} If they meet the study criteria, they will be invited to the Department of gynecology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine to undergo the study. All participants will be recruited through hospital social media (WeChat) or posters in the community and hospitals. If a patient is interested in participating, she will contact the researcher by WeChat or telephone. Prospective participants will be asked to talk face to face with the researcher for a baseline screening visit after diagnosis. Eligible participants will be randomized to acupuncture group or sham acupuncture group. There will be one year follow-up period after treatment.

2.4. Inclusion criteria

Patients who meet all of the following conditions will be considered for enrollment. The inclusion criteria are as follows:

1. females, aged between 20 and 45 years;
2. meet the diagnosis of HT with normal thyroid function (TSH<5.0mIU/L) and is trying to conceive;
3. willing to join this research and sign an informed consent form.

2.5. Exclusion criteria

The exclusion criteria are as follows:

1. infertility caused by organic lesions of the reproductive system or male infertility;
2. pregnant women or women in their lactation period;
3. complicated with bleeding disorders (for example, thrombocytopenia with bleeding tendency, coagulation disorder), mental diseases (serious anxiety and depression, schizophrenia), malignant tumor, or serious organic diseases;
4. history of radioiodine therapy or surgical intervention of the thyroid;
5. use of immunosuppressants, immunostimulants, or drugs that interfere with the production, transport, and metabolism of thyroid hormones (e.g., corticosteroids, lithium, and amiodarone);
6. participated in other clinical trials in the past 3 months.

2.6. Sample size

Sample size will be decided by the primary outcome. The primary outcome of this study will be the mean change of TPOAb and TGAb from baseline to week 12. According to the results of our previous pilot study, titers of TPOAb was 253.86 ± 178.23IU/ml in the acupuncture group and 318.98 ± 201.37IU/ml in the sham acupuncture group (TPOAb higher than 34IU/ml was the positive threshold of this research center). Considering participants
recruited in the two groups are in a 1:1 ratio, the following formula was used to estimate sample size:

\[ n = \left( \frac{Z_{\alpha/2} + Z_\beta}{\sigma} \right)^2 \]

With a 5% significance level (\(\alpha = 0.05\), two-sided) and 80% power (\(\beta = 0.2\)), at least 134 patients should be enrolled in each group and 284 total participants will be recruited to allow for a 10% dropout rate.

2.7. Randomization

As the cutoff value of LT4 supplementation based on TSH level is controversial in women who are trying to conceive, the participants will be stratified by TSH level (TSH < 2.5 mIU/L vs 2.5 mIU/L < TSH < 5 mIU/L). Once consent has been obtained and baseline data collected, participants will be randomized to the acupuncture group (n = 142) or the sham acupuncture group (n = 142). Randomization will be performed according to a random list of numbers generated with SPSS21.0 software (International Business Machines Corp., Armonk, NY). An
A independent researcher will prepare the assignments in opaque envelopes containing an allocation sequence number and take charge of the allocation sequence concealment.

2.8. Blinding

Due to the specific nature of the intervention, blinding will be maintained for participants, the data collection researcher, and the statistician except for the acupuncturist. The acupuncturist, the data collection researcher, and data analysts are not allowed to exchange information.

3. Interventions

There will be 4 weeks for baseline, 12 weeks for treatment, and 1 year for follow-up in this study. Each participant will receive 36 sessions of 30-minute duration over 12 weeks (3 times per week, once every 2–3 days). Participants whose TSH is greater than 2.5 mIU/L should be managed with a typical starting dose LT4 (25 mcg/d). TSH levels should be optimized to < 2.5 mIU/l, before conception. No additional treatment is allowed during treatment. Only licensed acupuncturists who have more than 5 years of experience will perform the treatment following the standardized operating procedures. The two groups of participants will be treated separately in different rooms to avoid communication between the participants. Each participant will take a supine position on the treatment couch which is separated by a curtain. Stick adhesive pads and disposable, sterile needles (gauge: 0.25 × 25 mm or 0.25 × 40 mm; Hwato, Suzhou, China)) will be used for acupuncture.

4. Acupuncture group

Participants in acupuncture group will receive therapy at the Lianquan (RN23), Renying (ST9), Danzhong (RN17), Guanyuan (RN4), Qihai (RN6), Zusanli (ST36), Sanyinjiao (SP6) and Zhaohai (KI6) points. The acupuncture points are identified according to the method of point location issued by the WHO. After local area disinfection with alcohol wipes, RN4, RN6, ST36, KI6 and SP6 will be inserted perpendicularly 10 to 15 mm deep with a 0.25 mm × 40 mm acupuncture needle. RN17 (with the needle tip pointing towards the head) will be punctured obliquely 5 to 10 mm deep with a 0.25 mm × 25 mm acupuncture needle, while RN23 (with the needle tip pointing towards the root of tongue) will be punctured obliquely to the depth of 5 mm. ST9 will be punctured perpendicularly to a depth of 5 mm. De qi sensation (a compositional sensation including numbness, soreness, distention, heaviness) will be achieved through lifting, thrusting, and rotating.

5. Sham acupuncture group

Participants in the control group will undergo treatment with a special sham acupuncture device with a blunt-tip needle (customize from Suzhou Huatu Medical Devices Co. Ltd.) which is similar to Streitberger needles device, without insertion.[59] This non-invasive placebo needles can provoke a needling sensation as soon as it touches the skin. The acupoint selection and procedures will be the same as in the acupuncture group. The acupuncturists should pretend to manipulate the needle for 10 seconds on each point as well. No deqi sensation will be induced.

6. Outcome measures

6.1. Primary outcome

The primary outcome in this trial is the titers of TPOAb and TGAb at baseline and at the 4th, 8th, and 12th week after randomization.

---

Table 1

| Visits          | Screening | Randomization | Treatment | Follow-up |
|-----------------|-----------|---------------|-----------|-----------|
|                 | 1         | 2             | 3 4 5     | 6 7       |
| Time Point      | 4 weeks † | Day 0         | Week 1 to 4| Week 5 to 8| Week 9 to 12| 6 mo After Treatment | 1 yr After Treatment |
| Baseline parameter |          |               |           |           |           |                    |                    |
| Age             | X         |               |           |           |           |                    |                    |
| Duration of disease |         |               |           |           |           |                    |                    |
| Disease history  | X         |               |           |           |           |                    |                    |
| Comorbidity      | X         |               |           |           |           |                    |                    |
| Concomitant medication | X     | X             | X         | X         | X         | X                   |                    |
| Clinical examination | X       |               |           |           |           |                    |                    |
| Intervention     |           |               |           |           |           |                    |                    |
| Acupuncture      |           |               |           |           |           |                    |                    |
| Sham acupuncture |           |               |           |           |           |                    |                    |
| Outcome assessment |         |               |           |           |           |                    |                    |
| Thyroid function | X         | X             | X         | X         | X         |                    |                    |
| Ovarian function | X         |               | X         | X         | X         |                    |                    |
| Primary ovarian insufficiency (%) |   |               | X         | X         | X         |                    |                    |
| Data collection and statistical analysis | | | | | | | |
| Adverse events   | X         | X             | X         |           |           |                    |                    |
| Causes of dropout | X       | X             | X         | X         | X         |                     |                    |
| Data analysis    |           |               |           |           |           |                    |                    |

Schedule for treatment and outcome measurements.

TPOAb = Thyroid peroxidase antibodies, TGAb = Thyroglobulin antibody.
6.2. Secondary outcomes

The secondary outcomes include:

1. thyroid function test including free triiodothyronine (fT3), free thyroxine (fT4), and thyroid stimulating hormone (TSH);
2. ovarian function including Anti Mullerian Hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2);
3. pregnancy outcome including pregnancy rate (%), pregnancy losses (%), and live birth rate (%);
4. primary ovarian insufficiency (%).

The thyroid function test will be performed at the baseline, 4th, 8th, and 12th week after randomization. The ovarian function will be examined on the 2nd to 4th day of the menstrual period in the 1st month, 2nd month and 3rd month compared with baseline (-1st month). Both the pregnancy outcome and the rate of primary ovarian insufficiency will be evaluated at 6 months and 1 year after treatment.

6.3. Assessment of adverse events

Any adverse events, including acupoint hematoma, bleeding, fainting, serious pain, infection, stuck needles, and broken needles, will be recorded by the researcher. If adverse events occur during the intervention, management will be taken emergently. Serious adverse reactions will be reported to the ethical committee and rescue procedures will be initiated at once.

6.4. Quality control and trial monitoring

Before the trial, all researchers involved will receive specialized training to maintain the study quality. The training courses include how to select and exclude patients, how to stratified randomization, how to manipulate interventions correctly, how to fill the case report form, how to assess outcomes and manage data. When the clinical trial begins, the principle researcher will supervise the trial. The licensed acupuncturists who have more than 5 years of experience will perform intervention according to the pre-specified standard operating procedure. Raw data will be recorded in the case record form (CRF). Two data managers enter the data into the spreadsheet and check the electronic data respectively. To guarantee the objectivity of the data, effect assessment and statistics will be blinded during the study period. Measures are taken to improve compliance, such as health education, respect patients informed consent right sufficiently etc.

6.5. Statistical analysis

Statistical analyses of data will be performed using SPSS21.0 software (International Business Machines Corp., Armonk, NY) by professionals who will be blinded to the whole trial process. According to the principle of intention-to-treat (ITT), all randomized participants will be analyzed. Continuous variables with normal distribution will be expressed as Mean±Standard Deviation (M±SD) and compared by an independent sample Student \( t \) test. For abnormally distributed variables, they will be expressed as Medians±Interquartile Range (MIQR) and non-parametric tests will be used. Categorical variables will be presented by frequency and percentage and analyzed by \( \chi^2 \) test or Fisher exact test. A repeated-measures multivariate analysis of variance (ANOVA) will be used to analyze value changes of TPOAb, TGAb, fT3, fT4, TSH, thyroxine, AMH, FSH, LH, and E2 across 4 testing time points (See Table 1). The rest of the secondary outcomes will compare the proportions of patients with primary ovarian insufficiency and different pregnancy outcome. Safety analyses will be compared with the incidence of AEs in two groups using the \( \chi^2 \) test. Missing data will be handled by multiple imputation methods. All the tests will be two-sided, and a \( P \) value of less than .05 will be considered statistically significant.

7. Discussion

Thyroid dysfunction and autoimmune in women of child-bearing age are adverse risk factors for fertility and pregnancy.\(^{[36]}\) The presence of anti-thyroid antibodies has increased risk of unexplained infertility, low fertilization rates, poor embryo quality in assisted reproductive technologies, miscarriage, preterm delivery, perinatal mortality, and maternal post-partum thyroiditis.\(^{[4,24]}\) The relationship between reproductive failure and autoimmune conditions (including thyroid disease) has attracted worldwide attention in recent years.\(^{[60]}\) Consider that the early and middle stages of adulthood are periods of increased risk for many autoimmune diseases, particular emphasis was placed on the importance of reproductive problems in these groups.\(^{[61]}\) The association between TPOAb and subfertility has proposed several possible mechanisms\(^{[21]}\):

1. The autoimmune process may lead to subfertility or pregnancy loss;
2. Infertility or pregnancy abortion may be secondary to hypothyroidism. An increased risk of unexplained infertility for the euthyroid women who were positive for thyroid antibodies.\(^{[24]}\)

Prolonged mild hypothyroidism may have a negative impact on the ovarian follicular reserve.\(^{[62]}\) There is no specific treatment modality to suppress autoimmune destruction by modern medicine, therefore, seeking complementary and alternative therapy such as acupuncture in the early stage is of great significance for the treatment and fertility preservation in the child-bearing period female with HT.

Acupuncture therapy has been used in clinical practice on thyroid disease for a long time. Currently, there is a lack of high-quality research and evidence on acupuncture for Hashimoto’s thyroiditis. Therefore, we are conducting a randomized controlled study to evaluate the effect of acupuncture on halting or delaying the progression of HT and fertility improving in the child-bearing period female. To reduce the possible bias, we use the stratified randomization method to randomize the enrolled patients into acupuncture group and sham acupuncture group. Due to the particularity of this invasive operation of acupuncture, completely inert placebo acupuncture and blinding is difficult in acupuncture trials. For the placebo control and better blinding of the participants, we use tailor-made sham needles and adhesive pads to treat participants alone in a separate room which is separated by a curtain. There is no definitively recommendation or objection to treatment with levothyroxine in euthyroid women who are positive for thyroid antibodies before pregnancy. In women seeking pregnancy through assisted reproductive technologies, the guidelines recommend levotyroxine treatment of subclinical hypothyroidism, defined as a TSH > 2.5 mIU/L in many studies, with a goal for the TSH of <2.5 mIU/L\(^{[50]}\) Levothyroxine supplementation may improve fertility in infertile patients.\(^{[63,64]}\) Given that there may be some benefit and negative influence may be avoided with adequate levothyroxine therapy.
aimed at keeping TSH <2.5mIU/L, we will manage the participants whose TSH is greater than 2.5mIU/L with a typical starting dose LT4 (25 µg/d).

Thyroid peroxidase (TPO) and thyroglobulin(TG) are involved in thyroid autoimmunity as important antigens.[6,5] TPO is the key enzyme in thyroid hormone synthesis.[66] The thyroid hormones T3 and T4 are synthesized in the thyroid gland in a process that crucially involves the iodoglycoprotein thyroglobulin (TG).[67] Antibodies against the main thyroid antigens (such as TPOAb and TGAAb) can induce a chronic lymphocytic thyroiditis, eventually leading to the destruction and loss of thyroid function.[21,68] TGAAb may reflect a more initial type of immune response, while TPOAb can characterize later adaptive immune response, a sort of immune escalation. Positive TPOAb and/or positive TGAAb, have been used test for screening for HT.[69] TPOAb (positive in 95% of HT patients) as the best serological marker of HT is more sensitive than TGAAb (positive in only 60%–80% of HT patients).[7,70] Some surveys suggest that positive TPOAb are associated with an increased risk of developing hypothyroidism.[11,12] In a cohort study, a TPOAb level above the threshold of 500IU/mL was associated with a moderately increased risk for developing hypothyroidism.[11] The presence of TPOAb negatively influences folliculogenesis, spermatogenesis, fertilization rates, embryo quality and pregnancy rates.[71] In Chinese women, idiopathic low ovarian reserve is associated with more frequent positive TPOAb.[12] Therefore, TPOAb and TGAAb will be used as the primary outcome to assess the effect of acupuncture on delaying or preventing disease progression and improving fertility in child-bearing period female with HT. Except for thyroid antibodies, evaluation of thyroid function in patients with HT is carried out by measuring the serum levels of thyrotropin (TSH), free thyroxine (FT4), free triiodothyronine (FT3).[7] Anti-Mullerian hormone (AMH) is secreted by the granulosa cells of growing ovarian follicles.[72] AMH is a suitable biomarker of ovarian age in women of reproductive age and the most widely used and reliable serum biomarker of ovarian reserve.[61,73] Follicle stimulating hormone (FSH) stimulates growth of ovarian follicles and aromatase expression in follicle granulosa cells. During reproductive aging in females, a rise in basal FSH is considered a sign of the reduction in the follicle reserve.[74] Basal estradiol level is usually lower than 50pg/mL. It can indicate reproductive aging and hastened oocyte development if greater than 60 to 80pg/mL in the early follicular phase.[75] Luteinizing hormone (LH) plays an essential physiological role in follicle steroidogenesis and development and oocyte maturation. High basal LH levels are associated with significantly reduced fertilization rates and oocyte maturation, as well as impaired embryo quality, consequently resulting in an impaired pregnancy rate and higher miscarriage rate.[76,77] Collectively, ovarian function will be assessed using the basal endocrine in the early follicular phase.

Acupoint selection has focused on Traditional Chinese medicine (TCM) theory or the treatment effects of acupuncture in this trial. SP6 and ST36 have been usually set for studies on endocrine disorder or reproductive syndrome.[78,79] Electro-acupuncture (EA) at the Guanyuan (RN4) or Sanyinjiao (SP6) can regulate hormone (E2, FSH, LH, GnRH) levels in the HPO axis.[80] Acupuncture from Renying (ST9) to Shuixi (ST10) can regulate neuro-immune-endocrine system to return thyroid hormone levels to normal and reduce the titer of antithyroid antibody.[81] EA at Guanyuan (RN4) and Zusanli (ST36) has benign regulating effects on the key hormones of pituitary-target gland axis, such as FSH, LH, E2, TSH, T3, and T4.[33] Lianquan (RN23), Renying (ST9), Danzhong (RN17), Guanyuan (RN4) and Qihai (RN6) points are located in Ren meridian which runs along the anterior median line of body and means dominating pregnancy. The thyroid gland is closely related to the Ren meridian because it is located in the anterior neck. According to the basic principles of acupoint indications, acupuncture the points on Ren meridian can regulate the qi of Ren meridian to treat thyroid diseases and improve fertility. Lianquan (RN23) and Renying (ST9) in the anterior neck near the thyroid gland can regulate thyroid function directly. Zhaohai (KI6) as one acupoint of Foot-Shaoyin connects with Ren meridian to treat thyroid disease.

A limitation in this trial is that the acupuncturists cannot be blinded due to the nature of the intervention. We hope the results will provide reliable evidence and clarify the value of acupuncture as a treatment for child-bearing period female with HT.

Author contributions
Conceptualization: Fangyuan Li, Zhang Qi, Lu Hua.
Investigation: Xinxin Wang.
Supervision: Mi Ling, Du Juan.
Writing – original draft: Fangyuan Li, Zhang Qi.
Writing – review & editing: Fangyuan Li, Lu Hua.

References
[1] Hiromatsu Y, Satoh H, Amino N. Hashimoto’s thyroiditis: history and future outlook. Hormones (Athens) 2013;12:12–8.
[2] McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012;42:52–65.
[3] Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853–78.
[4] Thangaratnam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BJM 2011;342:d2616.
[5] Caccavo D, Pellegrino NM, Nardelli C, et al. Anti-laminin-1 antibodies in serum and follicular fluid of women with Hashimoto’s thyroiditis undergoing in vitro fertilization. Int J Immunopath Pharmacol 2016;29:280–7.
[6] Polyzos NP, Sakkas E, Vaiarelli A, et al. Thyroid autoimmunity, hypothyroidism and ovarian reserve: a cross-sectional study of 5000 women based on age-specific AMH values. Hum Reprod 2015;30:1690–6.
[7] Catargi P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014;13:391–7.
[8] Baric A, Bečić L, Gračan S, et al. Association of established hypothyroidism-associated genetic variants with Hashimoto’s thyroiditis. J Endocrinol Invest 2017;40:1061–7.
[9] Pearce Elizabeth N, Farwell Alan P, Braverman Lewis E. Thyroiditis. N Engl J Med 2003;348:2646–55.
[10] Boivato L, Bassi P, Santini F, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J Clin Endocrinol Metab 1993;77:1700–5.
[11] Ehlers M, Jordan AL, Feldkamp J, et al. Anti-Thyroperoxidase Antibody Levels >500 IU/mL Indicate a Moderately Increased Risk for Developing Hypothyroidism in Autoimmune Thyroiditis. Horm Metab Res 2016;48:623–9.
[12] Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995;43:55–68.
[13] Practice Committee of the American Society for Reproductive Medicine/Subclinical hypothyroidism in the infertile female population: a guideline. Fertil Steril 2015;104:545–53.
[14] Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526–34.
[15] Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99.

[16] Dittrich R, Beckmann MW, Öppelt PG, et al. Thyroid hormone receptors and reproduction. J Reprod Immunol 2011;90:58–66.

[17] Dittrich R, Beckmann MW, Oppelt PG, et al. Thyroid hormone receptors and reproduction. J Reprod Immunol 2011;90:58–66.

[18] Dosiou C. Thyroid and fertility: recent advances. Thyroid 2020;30:479–86.

[19] Saglam F, Oral ED, Esoy R, et al. Anti-Müllerian hormone as a marker of premature ovarian aging in autoimmune thyroid disease. Gynecol Endocrinol 2015;31:165–8.

[20] Li Y, Shan Z, Teng W, et al. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months. Clin Endocrinol (Oxf) 2010;72:825–9.

[21] Visenberg R, Manterding V, Mastenbroek S, et al. Pathophysiological aspects of thyroid hormone disorders/thyroid peroxidase autoantibodies and reproduction. Hum Reprod Update 2015;21:378–87.

[22] Sun X, Heo N, Wang H, et al. A meta-analysis of pregnancy outcomes with levothyroxine treatment in euthyroid women with thyroid autoimmunity. J Clin Endocrinol Metab 2020;105:1009–19.

[23] Quintino-Moro A, Zantut-Wittmann DE, Tambascia M, et al. High prevalence of infertility among women with Graves’ disease and Hashimoto’s thyroiditis. Int J Endocrinol 2014;2014:982705.

[24] van den Boogaard E, Vissenberg R, Land JA, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update 2013;19:605–19.

[25] Bellver J, Soares SR, Alvarez C, et al. The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. Hum Reprod 2008;23:2784–8.

[26] Poppe K, Glinoer D, Van Steirteghem A, et al. Thyroid dysfunction and reproduction. J Reprod Immunol 2011;86.

[27] Betterle C, Rossi A, Dalla Pria S, et al. Premature ovarian failure: an integrated approach. Am Fam Physician 2014;90:389–96.

[28] Stoian D, Pantea S, Margan M, et al. Individualized follow-up of pregnant women with asymptomatic autoimmune thyroid disease. Int J Mol Sci 2016;17:88.

[29] Saglam F, Kuroda K, Segawa T, et al. Levothyroxine supplementation improves serum anti-Mullerian hormone levels in infertile patients with Hashimoto’s thyroiditis. J Obstet Gynecol Res 2018;44:739–46.

[30] Alexander KE, Pearce EN, Brent GA, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017;27:315–89.

[31] Cheng FK. An overview of the contribution of acupuncture to thyroid disorders. J Integr Med 2018;16:375–83.

[32] Hwang JH, Jung HW, Kang SY, et al. Therapeutic effects of acupuncture with MOK, a polyherbal medicine, on PTU-induced hypothyroidism in rats. Exp Ther Med 2018;16:310–20.

[33] Dong YZ, Zhao JM, Rao CH, et al. The research and Prospect of acupuncture and moxibustion on Hashimoto’s thyroiditis. J Acupunct Tuina Sci 2016;14:443–9.

[34] Shou Y, Hu L, Zhang W, et al. Determination of electroacupuncture effects on circRNAs in plasma exosomes in diabetic mice: an RNA-sequencing approach. Evid Based Complement Alternat Med 2019;2019:7534049.

[35] Hao Q, Wu S, Liu JM, et al. Effects of electroacupuncture with branch-foundation acupuncture combination on the pituitary-target gland axis in aging rats with Yang deficiency. Zhongguo Zhen Jiu 2014;34:993–7.

[36] Schulz KG, Altman DG, Moher D. CONSORT GroupCONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010;7:e1000251.

[37] MacPherson H, Altman DG, Hammerschlag R, et al. Revised STAndards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT Statement. Austr J Acupunct Chin Med 2010;7:35–46.

[38] Idampon-Heckelje JL. Ethical principles for the guidance of physicians in medical research—the Declaration of Helsinki. Bull World Health Organ 2001;79:279.

[39] Streitberger K, Klemmchen J. Introducing a placebo needle into acupuncture research. Lancet 1998;352:364–5.

[40] Safarian GK, Gzgayan AM, Dzemkhkanova Lyalika Y, et al. Does subclinical hypothyroidism and/or thyroid autoimmunity influence the IVF/IVCISI outcome? Review of the literature. Gynecol Endocrinol 2019;35(suppl 1):56–9.

[41] Somers FC, Marder W. Infertility - Prevention and Management. Rheum Dis Clin North Am 2017;43:275–85.

[42] Meng L, Rijnjes E, Swarts HJ, et al. Prolonged hypothyroidism severely reduces ovarian follicular reserve in adult rats. J Ovarian Res 2017;10:19.

[43] Abdel Rahman AH, Aly Abbassy H, Abbassy AA. Improved in vitro fertilization outcomes after treatment of subclinical hypothyroidism in infertile women. Endocr Pract 2010;16:792–7.

[44] Velkeniers B, Van Meerhaeghe A, Poppe K, et al. Levothyroxine treatment and pregnancy outcome in women with subclinical hypothyroidism undergoing assisted reproduction technologies: systematic review and meta-analysis of RCTs. Hum Reprod Update 2013;19:253–8.
